Европейский союз - испанский - EMA (European Medicines Agency)

astrazeneca ab  - metformina clorhidrato, saxagliptin clorhidrato de - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze está indicado como complemento de la dieta y el ejercicio para mejorar el control glucémico en pacientes adultos de 18 años de edad y mayores con diabetes mellitus tipo 2 inadecuadamente controlan con su dosis máximo tolerada de metformina sola o los que ya tratados con la combinación de saxagliptina y metformina como tabletas separadas. komboglyze también está indicado en combinación con insulina (i. terapia de combinación triple) como complemento a la dieta y el ejercicio para mejorar el control glucémico en pacientes adultos mayores de 18 años con diabetes mellitus de tipo 2 cuando la insulina y metformina por sí solos no proporcionan un adecuado control de la glucemia.

Европейский союз - испанский - EMA (European Medicines Agency)

astrazeneca ab - olaparib - neoplasmas ováricos - agentes antineoplásicos - ovario cancerlynparza está indicado como monoterapia para el:tratamiento de mantenimiento de pacientes adultos con avanzada (figo etapas iii y iv) en los genes brca1/2 mutación de la línea germinal (y/o somáticas) de alto grado epitelial de ovario, de trompa de falopio o peritoneal primario de cáncer que están en la respuesta (parcial o completa) después de la finalización de la primera línea de quimioterapia basada en platino. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 y 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. los pacientes deben haber sido tratados previamente con una antraciclina y un taxano en el (neo)adyuvante o metastásico (a menos que los pacientes no eran adecuadas para estos tratamientos (véase la sección 5. los pacientes con receptores hormonales (rh) positivo de cáncer de mama deben también han progresado en o después de antes de la terapia endocrina, o ser considerados no aptos para la terapia endocrina. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Европейский союз - испанский - EMA (European Medicines Agency)

cis bio international - trifluoroacetato de la depreotida - imágenes de radionúclidos - radiofármacos de diagnóstico - este medicamento es solo para uso diagnóstico. para gammagráficos de imágenes de sospecha de tumor maligno en el pulmón después de la detección inicial, incombination con tac o la radiografía de tórax en los pacientes con nódulos pulmonares solitarios.

Европейский союз - испанский - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoato, metformin hidrocloruro - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. terapia de combinación triple) como complemento a la dieta y el ejercicio para mejorar el control glucémico en los pacientes cuando la insulina en una dosis estable y metformina por sí solos no proporcionan un adecuado control de la glucemia.

Европейский союз - испанский - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-ácido piroglutámico, la sitagliptina fosfato monohidrato - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - steglujan está indicado en adultos mayores de 18 años con diabetes mellitus tipo 2 como un complemento a la dieta y el ejercicio para mejorar el control de la glucemia:cuando la metformina y/o sulfonilureas (su) y uno de los monocomponents de steglujan no proporcionan un adecuado control de la glucemia. en los pacientes que ya estén siendo tratados con la combinación de ertugliflozin y la sitagliptina como independiente tabletas.

Европейский союз - испанский - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - diabetes mellitus, tipo 2 - drogas usadas en diabetes - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 y 5.

Европейский союз - испанский - EMA (European Medicines Agency)

gilead sciences ireland unlimited company - lenacapavir sodium - infecciones por vih - antivirales para uso sistémico - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 y 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 y 5.

Европейский союз - испанский - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agentes antineoplásicos - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Европейский союз - испанский - EMA (European Medicines Agency)

bayer ag - riociguat - hipertensión, pulmonar - antihipertensivos para la hipertensión arterial pulmonar - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. la eficacia se ha demostrado en un pah la población, incluyendo a las etiologías de la idiopático o hereditario hap o pah asociada con enfermedad del tejido conectivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Европейский союз - испанский - EMA (European Medicines Agency)

teva b.v. - salmeterol, propionato de fluticasona - pulmonary disease, chronic obstructive; asthma - medicamentos para la enfermedad obstructiva de las vías respiratorias enfermedades, - airexar spiromax está indicado solo en adultos mayores de 18 años.. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. la enfermedad pulmonar obstructiva crónica (epoc)airexar spiromax está indicado para el tratamiento sintomático de pacientes con epoc, con un fev1.